These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

259 related items for PubMed ID: 22642935

  • 1. Incidence, predictors and significance of severe toxicity in patients with human immunodeficiency virus-associated Hodgkin lymphoma.
    Ezzat HM, Cheung MC, Hicks LK, Boro J, Montaner JS, Lima VD, Harris M, Leitch HA.
    Leuk Lymphoma; 2012 Dec; 53(12):2390-6. PubMed ID: 22642935
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. [Effectiveness and toxicity of MOPP, ABVD, BEACOPP chemotherapy in first-diagnosed Hodgkin lymphoma with a poor prognosis].
    Filatova LV, Plotnikova AA, Gershanovich ML, Semiglazova TIu.
    Vopr Onkol; 2013 Dec; 59(2):59-65. PubMed ID: 23814851
    [Abstract] [Full Text] [Related]

  • 7. Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin's disease: report of an intergroup trial.
    Duggan DB, Petroni GR, Johnson JL, Glick JH, Fisher RI, Connors JM, Canellos GP, Peterson BA.
    J Clin Oncol; 2003 Feb 15; 21(4):607-14. PubMed ID: 12586796
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Can MOPP be replaced in the treatment of advanced Hodgkin's disease?
    Canellos GP.
    Semin Oncol; 1990 Feb 15; 17(1 Suppl 2):2-6. PubMed ID: 1689509
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. HIV status does not influence outcome in patients with classical Hodgkin lymphoma treated with chemotherapy using doxorubicin, bleomycin, vinblastine, and dacarbazine in the highly active antiretroviral therapy era.
    Montoto S, Shaw K, Okosun J, Gandhi S, Fields P, Wilson A, Shanyinde M, Cwynarski K, Marcus R, de Vos J, Young AM, Tenant-Flowers M, Orkin C, Johnson M, Chilton D, Gribben JG, Bower M.
    J Clin Oncol; 2012 Nov 20; 30(33):4111-6. PubMed ID: 23045581
    [Abstract] [Full Text] [Related]

  • 16. Fifteen-year secondary leukaemia risk observed in 761 patients with Hodgkin's disease prospectively treated by MOPP or ABVD chemotherapy plus high-dose irradiation.
    Delwail V, Jais JP, Colonna P, Andrieu JM.
    Br J Haematol; 2002 Jul 20; 118(1):189-94. PubMed ID: 12100147
    [Abstract] [Full Text] [Related]

  • 17. Cardiopulmonary response to exercise in patients with different degrees of lung toxicity after radio-chemotherapy for Hodgkin's disease.
    Villani F, Busia A, Villani M, Laffranchi A, Viviani S, Bonfante V.
    Anticancer Res; 2009 Feb 20; 29(2):777-83. PubMed ID: 19331235
    [Abstract] [Full Text] [Related]

  • 18. Chemotherapy in the treatment of Hodgkin's disease.
    Canellos GP, Come SE, Skarin AT.
    Semin Hematol; 1983 Jan 20; 20(1):1-24. PubMed ID: 6189191
    [No Abstract] [Full Text] [Related]

  • 19. The role of chemotherapy in the management of early stage Hodgkin's disease.
    Rosenberg SA.
    Hematol Oncol; 1984 Jan 20; 2(1):61-3. PubMed ID: 6203821
    [No Abstract] [Full Text] [Related]

  • 20. Low acute hematological toxicity during chemotherapy predicts reduced disease control in advanced Hodgkin's disease.
    Brosteanu O, Hasenclever D, Loeffler M, Diehl V, German Hodgkin's Lymphoma Study Group.
    Ann Hematol; 2004 Mar 20; 83(3):176-82. PubMed ID: 15064867
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.